Absorption, Distribution, Metabolism, and Excretion (ADME) studies, along with biodistribution analysis, help determine the pharmacokinetics of your compounds and their behavior within the body, providing key insights into their efficacy and safety profiles.
ERBC performs comprehensive biodistribution studies using cutting-edge, non-invasive in vivo fluorescence imaging. This advanced technique allows us to track the distribution and retention of your compounds in living animals over time. Unlike traditional pharmacokinetics (PK) studies, which are typically conducted at terminal endpoints, our in vivo fluorescence imaging provides real-time insights into the biodistribution of various substances, including nanoparticles, nanomaterials, proteins, antibodies, and liposomes.
The combination of fluorescence imaging with bioluminescence further enables us to assess whether your compound colocalizes with specific pathological processes, offering a more detailed and accurate representation of how a drug behaves in the body. This is especially useful for studying disease models, ensuring that your compound reaches the target tissues effectively.
